A real-world data analysis of the impact of clonal hematopoiesis of…
A simple blood test may help doctors identify which advanced cancer patients will respond best to immunotherapy, potentially sparing others from ineffective treatment.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Umbilical cord blood natural killer cells improve anti-GD2 antibody…
Lab-grown immune cells from umbilical cord blood, combined with existing antibody therapy, show early promise against a deadly childhood cancer in the first treated patients.
Novel or significantly improved treatmentAmivantamab in advanced non-small cell lung cancer with epidermal…
A targeted drug for a tricky lung cancer mutation delivers meaningful survival gains with manageable side effects and notably penetrates the brain, where this cancer often spreads.
Near-term implementable findingOutpatient worsening heart failure in transthyretin amyloid cardiomyopathy
Detecting subtle worsening in heart failure through routine diuretic increases identifies high-risk patients who benefit from early preventive treatment in this rare cardiomyopathy.
Standard additionImproving salvage regimens prior to autologous stem cell…
Newer treatment combinations combined with genetic testing may help doctors spare some lymphoma patients from stem cell transplants while improving survival outcomes.